This page shows the latest morphosys news and features for those working in and with pharma, biotech and healthcare.
Tremfya, an anti-IL-23 monoclonal antibody, was developed using MorphoSys ’HuCAL antibody library technology, allowing the German biotech to collect royalties on Tremfya sales under a multiple target deal it ... Dr Simon Moroney, chief executive officer
BI 836845 is one of the drugs that has emerged from the company's long-standing antibody collaboration with MorphoSys, and is also being tested in combination with Novartis' Femara (exemestane)
It also has collaborations in place with AstraZeneca (AZ), Merck &Co's Cubist unit, MorphoSys and Takeda.
J/Morphosys.
A monoclonal antibody, bimagrumab was developed by the Novartis Institutes for Biomedical Research (NIBR) in collaboration with Morphosys, whose HuCAL library was used to identify the antibody.
GSK buys rights to MorphoSys' arthritis antibody. Pharma company will pay up 445m to develop and commercialise MOR103. ... Dr Simon Moroney, CEO of MorphoSys, described the deal as a “ major milestone” for the company. “
More from news
Approximately 1 fully matching, plus 11 partially matching documents found.
acquisition - company. 125+. MorphoSys/ Leo Pharma. discovery and development of mAbs for skin diseases.
In the same area is Morphosys which has been less fortunate this month because of the termination of its $818m agreement with Celgene to develop a Mab for treatment of multiple ... myeloma. Morphosys' share price fell by over 20%. This is an
187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).
These include the usual sprinkling of small molecule (Millennium/ Infinity, Hanmi/ Luye, Ziopharm/ Solasia) and antibody (Emergent/ Morphosys) approaches but also more alternative approaches as exemplified by the Gamida/ Novartis agreement.
Joining the checkpoint modulator fray, Merck Serono formed a partnership with Morphosys to discover and develop antibodies against certain immune checkpoints using the Morphosys Ylanthia platform.
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
He has previously held roles for ProQR Therapeutics, Janssen BioTherapeutics, and MorphoSys.
He has also held roles with MorphoSys and Hoffman La Roche.
MorphoSys appoints Dr Markus Enzelberger as CSO. He succeeds Dr Marlies Sproll who resigns. ... German biotech MorphoSys has appointed Dr Markus Enzelberger as its new chief scientific officer following his predecessor, Dr Marlies Sproll’s resignation.
MC Services welcomes Dr Claudia Gutjahr-Loeser to its management team. She joins the PR firm from MorphoSys, where she was senior VP. ... She joins the Duesseldorf, Germany-based firm from MorphoSys, where she headed the corporate communications and
He joins from MorphoSys, where he has been chief development officer since 2008, overseeing a portfolio of therapeutic antibody programmes in oncology and immunology. ... His strong management expertise developed at both MorphoSys AG and Genentech as
More from appointments
Approximately 3 fully matching, plus 5 partially matching documents found.
Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...